None listed
Conditions
Interventions
Drug : CV1 group take 1 sachet (3.75g) of Cracie Bojungikgi-tang extract twice a day before or between meals. CV2 group take 1 sachet (20g) of Gyeongbang Gyeongok-go twice a day in the morning and eve
Sponsors
Korea Institute of Oriental Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Persons 19 years of age or older who have been diagnosed with COVID-19 and have been completely cured - Those who have continuously experienced fatigue or brain fog that they did not experience before being diagnosed with COVID-19 for more than 4 weeks - Those with a total score of 76 or higher on the Checklist Individual Strength (CIS) - Those who have no problems with overall cognitive function and who voluntarily consented to participate in the study through written consent form
Exclusion criteria
Exclusion criteria: - Those with or have a history of organic diseases that can cause fatigue (cancer, sleep disturbance, chronic hepatitis, liver cirrhosis, chronic renal failure, tuberculosis, asthma, multiple sclerosis) - Those with or have a history of organic diseases that can cause brain fog(cerebral hemorrhage, cerebral infarction, brain tumor, Parkinson's disease, epilepsy, major depressive disorder, bipolar affective disorder, schizophrenia, delusional disorder, dementia) - Those with genetic diseases that may affect the intake or absorption of drugs (dysphagia, clinically serious digestive disorders, galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption) - Those with or have a history of allergy to clinical trial drugs (oriental medicines) - Those with or have a history of liver disease or kidney disease, or AST, ALT, BUN, and creatinine in blood tests exceed 3 times the upper limit of normal - Women who are pregnant, may become pregnant or are lactating - In case of participating in another study within 30 days prior to participation in the clinical trial - Subjects who are judged to be inappropriate for the clinical study by the researchers due to clinically significant psychiatric symptoms, medical conditions, laboratory findings, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment success rate after taking herbal medicines for up to 12 weeks for fatigue and brain fog in patients who have recovered from COVID-19 | — |
Secondary
| Measure | Time frame |
|---|---|
| Final medication adherence;Differences in final medication adherence by herbal medicine administration group;CIS (checklist Individual Strength) scores;ChFS(Chalder Fatigue Scale) score and subscale score;EQ-5D-5L score;PSQI-K (Korean version of Pittsburgh Sleep Quality Index) Global score;K-MOCA(Korean-Montreal cognitive assessment) score;CFQ(Cognitive Failure Questionnaire) score;BDI (Becks’ depression inventory) score; DF(digit forward) score, DB(digit backward) score, DF-DB score; K-BNT-15 (the Korean Version-the Boston Naming Test-15) score;Analysis of target recruitment rate, dropout rate, and dropout reason for feasibility evaluation | — |
Countries
Korea, Republic of
Contacts
Public ContactTae-Hun Kim
Kyung Hee University Oriental Medical Center
Outcome results
None listed